Special Issue "Astaxanthin: A Potential Therapeutic Agent"
A special issue of Marine Drugs (ISSN 1660-3397).
Deadline for manuscript submissions: closed (15 June 2020) | Viewed by 60629
Interests: oxidative stress; cell&Molecular biology; biomedical engineering; antioxidants; natural actives; nanomaterials; drug delivery
Special Issues, Collections and Topics in MDPI journals
Special Issue in Pharmaceutics: Nanostructured Lipid Carriers for Drug Delivery Systems
Oxidative stress, inflammation, and apoptosis are some of the mechanisms involved in the pathogenesis of several diseases such as cardiovascular pathologies, neurodegenerative disorders, diabetes, and cancer. Founding new therapeutic molecules capable of maintaining cellular redox homeostasis and blocking oxidative stress are hallenges of crucial importance.
Because of its anti-inflammatory and antioxidant properties, astaxanthin, a xanthophyll carotenoid extracted from marine organisms and microalgae, has been proposed for repairing and protecting cells and tissues or as a nutraceutical/cosmeceutical ingredient to prevent oxidative stress-related diseases. Epidemiological studies suggest that astaxanthin prevents the free radical-dependent oxidation of LDL, cholesterol, proteins, or DNA, by capturing free radicals and by reducing stress induced by ROS.
This Special Issue aims to highlight recent research about astaxanthin’s potential as a therapeutic agent. Despite significant growing evidence suggesting that astaxanthin has a potential health-promoting effect in the prevention and treatment of several pathologies, research advances need to be reported. Original research (in vitro, in vivo, and clinical) and reviews to highlight the therapeutic potential effect of astaxanthin are encouraged to be presented in this Special Issue.
Dr. Graciela Pavon-Djavid
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2500 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- therapeutic agent
- oxidative stress
- clinical trials
- animal studies
- in vitro
- gene expression
- drug delivery